|
A Class Act in Glaucoma Management: Differentiating Rho Kinase Inhibitors From the Pack
Medical management of glaucoma primarily focuses on lowering intraocular pressure (IOP) by decreasing aqueous production, reducing episcleral venous pressure, and/or increasing uveoscleral and trabecular outflow. Recently approved agents have expanded treatment options beyond the traditional mainstays of prostaglandin analogues and β-blockers, engaging Rho kinase (ROCK) inhibition to improve outcomes for patients with glaucoma. In this CE monograph, experts in the field will review the clinic... |
|
Individualizing Glaucoma Treatment: Understanding How to Utilize Traditional and Novel Agents
Join Nathan M. Radcliffe, MD, and Justin Schweitzer, OD, FAAO, as they discuss the ways in which novel therapeutics may help to overcome the challenges and limitations associated with currently available pharmacologic treatment options for ocular hypertension and primary open-angle glaucoma. |